Analysts Offer Predictions for FibroGen FY2024 Earnings

FibroGen, Inc. (NASDAQ:FGEN) – Equities research analysts at HC Wainwright issued their FY2024 EPS estimates for shares of FibroGen in a research report issued to clients and investors on Tuesday, December 17th. HC Wainwright analyst M. Keller forecasts that the biopharmaceutical company will post earnings per share of ($0.74) for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for FibroGen’s Q4 2024 earnings at ($0.08) EPS and FY2025 earnings at ($0.53) EPS.

Several other research analysts have also recently weighed in on FGEN. William Blair reiterated a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th. StockNews.com began coverage on shares of FibroGen in a report on Monday. They set a “hold” rating for the company.

FibroGen Trading Up 2.7 %

Shares of NASDAQ FGEN traded up $0.01 during trading on Thursday, reaching $0.35. 362,583 shares of the company traded hands, compared to its average volume of 2,103,252. The stock has a market cap of $35.46 million, a P/E ratio of -0.29 and a beta of 0.82. The firm’s fifty day simple moving average is $0.35 and its 200 day simple moving average is $0.57. FibroGen has a 12-month low of $0.18 and a 12-month high of $2.93.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same quarter in the prior year, the firm earned ($0.52) earnings per share.

Institutional Investors Weigh In On FibroGen

Several hedge funds have recently modified their holdings of FGEN. Acadian Asset Management LLC raised its holdings in FibroGen by 34.4% in the 2nd quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after purchasing an additional 860,854 shares during the period. AQR Capital Management LLC increased its position in shares of FibroGen by 139.6% in the second quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after buying an additional 769,586 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of FibroGen during the 3rd quarter worth approximately $307,000. XTX Topco Ltd purchased a new position in shares of FibroGen during the 2nd quarter valued at approximately $424,000. Finally, Cubist Systematic Strategies LLC grew its stake in FibroGen by 3,906.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 280,161 shares during the period. 72.71% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.